Opdivo (Nivolumab)

Nivolumab, the active ingredient in Opdivo, is a monoclonal antibody presented as an intravenous solution for infusion use. It is employed in cancer immunotherapy, targeting specific tumor types in adult patients. GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Opdivo is an immunotherapy drug that targets the PD‑1 pathway and is indicated for several cancer types.

- Melanoma: Improves survival and disease‑free outcomes in patients with unresectable or metastatic disease. - Non‑small cell lung cancer (NSCLC): Extends the overall survival for patients with advanced NSCLC that is PD‑L1 positive or with high tumor mutation burden. - Renal cell carcinoma (RCC):       - Renal       -